In part 1 of this Exclusive Interview, Dr. Samuel Engel talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the results of the new SGLT-2, ertugliflozin.

In part 2 of this Exclusive Interview, Dr. Samuel Engel explains the effects of ertugliflozin on typical biometrics in a conversation with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California.

In part 3 of this Exclusive Interview, Dr. Samuel Engel talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the cardiovascular study portion of the ertugliflozin trial.

In part 4 of this Exclusive Interview, Dr. Samuel Engel talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about looking at the impact of DPP-4s on hypoglycemia.